MENLO PARK, Calif.--(BUSINESS WIRE)--PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC TherasightTM and Lupus TherasightTM. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.
